News

Boston Heart's Patrick Noland discusses blood-based antibody testing for COVID-19

The COVID-19 blood-based serology test looks for a type of antibodies that reflect having had active disease, and it's thought the best time to test for them is at 14 days after infection. The lab hopes to participate in research with local hospitals to monitor patients' immune response over time and possibly to help with efforts to develop treatments from antibodies.

The Eurofins’ U.S. Clinical Diagnostics network has launched an Antibody Test for hospital workers, first responders and patients. Testing will occur at Boston Heart Diagnostics, a Eurofins subsidiary.

Global testing company Eurofins announced it will begin offering large-scale, blood-based COVID-19 antibody testing in Massachusetts through its Viracor and Boston Heart Diagnostics subsidiaries.

Starting April 6, hospitals on the East Coast will be able to ship blood samples to Boston for analysis, according to Eurofins, which expects to start processing 200 tests per hour, or about 4,800 per day. Additionally, Viracor said it plans to offer its own test in mid-April.

Viracor's Dr. Steve Kleiboeker talks with Dr. Hyman on the The Doctor's Farmacy about who should be tested for COVID-19, when, and how, and what kinds of tests are currently available or soon will be. In addition, they discuss some of the most confusing COVID-19 recommendations, like if the general public should wear masks as a protective measure.

Eurofins U.S. Clinical Diagnostics Network's Boston Heart Diagnostics has launched a coronavirus COVID-19 antibody blood-based test for area hospitals—where the need is the highest ahead of an anticipated surge in the coming weeks.  The serology lab test may be able to identify if a person is immune to the highly contagious disease and could be the key in fighting the spread of the virus. 

The Eurofins’ U.S. Clinical Diagnostics network announced today that blood-based antibody testing for Coronavirus SARS-CoV-2 will begin Monday, April 6 at Boston Heart Diagnostics, a Eurofins subsidiary.  Given the overwhelming demand in acute care settings, the laboratories will initially offer the test to hospitals only.  As capacity increases, and as knowledge on the disease develops, the Eurofins’ network plans to begin offering testing more broadly

Labs@HOME is a mobile phlebotomy, at-home blood draw service for immunocompromised patients who must limit interaction in the hospital during the COVID-19 outbreak. This service will aid in specimen collection for vital post-transplant testing, directly from a patient’s home.

Viracor Eurofins said its labs are running up to 5,000 tests a day, many in 24 hours, but also said, “due to the backlog, unprecedented demand, pressures on our supply chain, and shipping delays … our turnaround time has been pushed beyond what we normally experience.

Transplant Genomics, Inc. today announced that it has partnered with sister Eurofins company Viracor, and established relationships with Quest and various mobile sample collection groups, to enable patients to have samples collected remotely for analysis with our unique catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.